Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study (Q64360391)

From Wikidata
Jump to navigation Jump to search
article by Martin R Gaudinski et al published 2 March 2019 in The Lancet
edit
Language Label Description Also known as
English
Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study
article by Martin R Gaudinski et al published 2 March 2019 in The Lancet

    Statements

    Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study (English)
    0 references
    0 references
    0 references
    0 references
    0 references
    0 references
    0 references
    0 references
    0 references
    0 references
    0 references
    0 references
    0 references
    0 references
    0 references
    0 references
    0 references
    0 references
    0 references
    0 references
    0 references
    0 references
    0 references
    0 references
    Eugeania Burch
    0 references
    Grace L Chen
    0 references
    Sandra Vazquez
    0 references
    Frank Arnold
    0 references
    Heather Lawlor
    0 references
    Jason Gall
    0 references
    Robert T Bailer
    0 references
    2 March 2019
    0 references
    0 references
    393
    0 references
    10174
    0 references
    889-898
    0 references

    Identifiers

     
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    edit